A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer

Recruiting

Phase 2

FF-10832 & PembrolizumabA Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer

Sponsor:

Fujifilm Pharmaceuticals U.S.A., Inc.

Code:

NCT05318573

Conditions

Advanced Urothelial Carcinoma

Advanced Non Small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Pembrolizumab

FF-10832

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-15. This information was provided to ClinicalTrials.gov by Fujifilm Pharmaceuticals U.S.A., Inc. on 2025-04-10.